Sanofi-aventis reveals latest rimonabant findings

Sanofi-aventis has revealed the latest results from testing of its rimonabant product at an industry event staged by the American Diabetes Association in San Francisco.

The drug is designed to help people who have type two diabetes but struggle to control the condition through insulin and the company has suggested that the product has strong potential.

When the patients with type two diabetes were given rimonabant, in addition to heeding lifestyle advice and taking insulin, they were found to be three times more likely to control their glucose levels than in the control groups.

“The Arpeggio trial demonstrated that there is still room for significant improvement in diabetic patients who despite several years of standard therapies,” said Priscilla L Hollander, coordinating investigator of the study.

Sanofi-aventis claims to be among the leading pharmaceutical firms in Europe and boasts a global workforce of around 100,000 people.